Voyager Therapeutics and Genzyme have entered into a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. The collaboration will leverage Genzyme's long-standing commitment and scientific leadership in the field of adeno-associated virus (AAV) gene therapy and Voyager's industry-leading AAV product engine to develop breakthrough therapies for patients suffering from severe CNS disorders.
The alliance will encompass multiple gene therapy programs, including programs for Parkinson's disease, Friedreich's ataxia and Huntington's disease, as well as other CNS disorders. The collaboration portfolio created will combine programs and intellectual property from both companies. Voyager will drive research and development activities for all programs, working with Genzyme in a highly collaborative way. Genzyme will have the option to license several programs following completion of an initial proof-of-concept human trial.
However, Voyager will retain all U.S. rights to its lead product programs in Parkinson's disease (VY-AADC-01) and Friedreich's ataxia (VY-FXN-01). Voyager will split U.S. profits with Genzyme for the Huntington's disease program (VY-HTT-01). In addition, Voyager's lead amyotrophic lateral sclerosis program (VY-SOD-101) is not part of the collaboration and Voyager retains worldwide rights to this program (Voyager Therapeutics News Release).